KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gilead Sciences (GILD) Accumulated Expenses (2016 - 2022)

Gilead Sciences (GILD) has disclosed Accumulated Expenses for 14 consecutive years, with $3.7 billion as the latest value for Q3 2022.

  • For the quarter ending Q3 2022, Accumulated Expenses rose 9.09% year-over-year to $3.7 billion, compared with a TTM value of $3.7 billion through Sep 2022, up 9.09%, and an annual FY2021 reading of $3.2 billion, down 6.24% over the prior year.
  • Accumulated Expenses was $3.7 billion for Q3 2022 at Gilead Sciences, up from $3.5 billion in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $5.0 billion in Q1 2018 and bottomed at $2.3 billion in Q3 2018.
  • Average Accumulated Expenses over 5 years is $3.4 billion, with a median of $3.4 billion recorded in 2021.
  • Peak annual rise in Accumulated Expenses hit 92.23% in 2018, while the deepest fall reached 50.06% in 2018.
  • Year by year, Accumulated Expenses stood at $3.9 billion in 2018, then dropped by 21.74% to $3.1 billion in 2019, then grew by 12.56% to $3.5 billion in 2020, then fell by 6.24% to $3.2 billion in 2021, then grew by 13.26% to $3.7 billion in 2022.
  • Business Quant data shows Accumulated Expenses for GILD at $3.7 billion in Q3 2022, $3.5 billion in Q2 2022, and $3.4 billion in Q1 2022.